Products are being developed which utilize novel and proprietary compounds which kill microbes (>6log reduction in 5 minutes) without contributing to the evolution of antimicrobial resistant microbes.

Viropin Pharmaceutical’s proprietary compounds are also being formulated as hospital sanitizers, decolonization oinytments, pre-surgical scubs and wound care solutions. These compounds will not contribute to the evolution of antimicrobial resistant microbes (unlike current sanitizers on the market).

Viropin Pharmaceutical has developed and is testing novel anti-viral products that would contribute to mitigating influenza A and B and potentially the next viral pandemic. The proprietary products are a combination of molecules, which act synergistically via different mechanisms.

This synergistic solution utilizes compounds which have already been proven to be safe for human-use in Phase-3 Clinical Trials.